dual orexin receptor GPCR antagonist

Ph. III efficacy for insomnia, oral 25-50 mg

from optimization of prior clinical candidate

ChemMedChem., Oct. 28, 2020

Idorsia Pharmaceuticals, Allschwil, CH

Idorsia clinical dual orexin receptor GPCR antagonist


 become a member to continue reading

Ask your company or librarian about a Drug Hunter membership to to see all summaries and get access to even more helpful information.

  • Stay up-to-date and save more time with exclusive members-only content
  • On-board new team members with educational content and case studies
  • Generate ideas and discussion with easy-to-read slide decks
  • Generate ideas and discussion with easy-to-read slide decks